Podcast - IR Department talks to Race Oncology's CSO Dr Daniel Tillett

Our Digital Content Producer, Paul Langley, talks with Race Oncology's CSO Dr Daniel Tillett, who explains how the recent clinical trials are evolving and what it means for the future. He gives a brief overview on the history of Race, their aspirations and milestones for development and eventual commercialisation of Zantrene.

August 29th, 2022 by Paul Langley
Read More

Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham

Our Communications Director, Cherie Hartley, talks with AdAlta's CEO & M.D. Dr Tim Oldham at this year's Bioshares Biotech Summit, who takes us inside the mind of a biotech company. He discussed the importance of focus for a platform company, explains why making decisions on a day-to-day basis is so crucial for risk reduction and why they're investing in supporting core strategies as well as their target product profile.

July 4th, 2022 by Cherie Hartley
Read More

IRD Invest March 2022 - Openpay

IRD Invest March 2022 - "Project: 2025"

Watch the replay of Openpay's CEO (Australia & New Zealand) Dion Appel.

March 31st, 2022 by Paul Langley
Read More

IRD Invest March 2022 - Oventus

IRD Invest 31st March 2022 - "Project: 2025"

Watch the replay of Oventus CEO John Cox's presentation.

March 31st, 2022 by Paul Langley
Read More

IRD Invest March 2022 - Pureprofile

IRD Invest 31st March 2022 - "Project: 2025"

Watch the replay of Pureprofile CEO Martin Filz's presentation.

March 31st, 2022 by Paul Langley
Read More

CEO in focus - Pureprofile's Martin Filz

March 24th, 2022 by Paul Langley
Read More

Servatus launches new trial into the effects of live biotherapeutics on insomnia

Servatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative.

March 24th, 2022 by Michael Lovesey
Read More

Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)

March 23rd, 2022 by Cherie Hartley
Read More

Recent client coverage highlights

March 23rd, 2022 by Paul Langley
Read More

Project: 2025

Join us on Thurs 31 March for "IRD Invest - Project 2025"

As we look to accelerate the integration of advanced technology over the next three years, our fourth IRD Invest conference considers some of the benefits this change will bring, for businesses and society.

We are delighted to showcase a select number of emerging ASX listed tech companies on 31 March. The free virtual event will focus on companies that are paving the way forward with major advances in technology and innovation.

March 21st, 2022 by Admin
Read More

XPON’s CEO Matt Forman's presentation to the ASX Small – Mid Cap CEO conference

XPON’s CEO Matt Forman's presentation to the ASX Small – Mid Cap CEO conference

March 17th, 2022 by Jane Lowe
Read More

Interview with Ben Fogarty, CEO (UK) XPON

We speak to Ben Fogarty, CEO (UK & Europe) from XPON Technologies Group (see video below) about what the future holds for them and the impact of the upcoming ‘Metaverse’.

March 17th, 2022 by Paul Langley
Read More